XIE Shuwu, Ph.D. in Pharmacology, currently serving as Deputy Director of the Shanghai Laboratory Animal Research Center. He also serves as Secretary-General of the Reproductive Pharmacology Specialized Committee of both the Chinese Pharmacological Society and the Shanghai Pharmacological Society, Evaluation Expert for Government Procurement of the National Health Commission and the Ministry of Finance, and Evaluation Expert for the National Natural Science Foundation of China, among other positions.

XIE Shuwu has published over eighty papers and filed more than ten invention patent applications. He has contributed to the compilation of multiple books, including the 4th edition of Pharmacological Experimental Methodology, Report on the Development of Pharmacology, and Pharmacological Methodology Research. He has undertaken projects funded by the National Natural Science Foundation of China and the Shanghai Natural Science Foundation, among other national and provincial or ministerial-level programs. As a key project member, he has participated in three supporting projects under the Ministry of Science and Technology's 12th Five-Year Plan and one project under the National Key Research and Development Program of the 13th Five-Year Plan, as well as projects funded by the former National Health and Family Planning Commission, Shanghai Municipal Science and Technology Commission, Shanghai Municipal Health Commission, and Shanghai Municipal Education Commission. He has participated in the research and development of two Class II new drugs, "Levonorgestrel and Ethinylestradiol Contraceptive Patch" and "Compound Gestodene Patch," for which two Clinical Research Approvals have been obtained. He received one Third Prize of the Outstanding Scientific and Technological Achievement Award from the National Health and Family Planning Commission during the 11th Five-Year Plan period.

He has established animal and cell models for reproductive diseases, including epididymal infertility, dysmenorrhea, miscarriage, pregnancy, uterine fibroids, endometriosis, endometrial cancer, and ovarian cancer, utilizing drug induction, surgical, and gene modification techniques. Integrating molecular biology and molecular oncology, he has collaborated with multiple renowned domestic pharmaceutical companies and research institutions, including Beijing Zizhu Pharmaceutical, Runhe Biomedicine, Shanghai Institute of Materia Medica of the Chinese Academy of Sciences, Second Military Medical University (now Naval Medical University), and Shanghai Institute of Pharmaceutical Industry, on new drug research and development. His key research projects include "Screening and Identification of Epididymal Luminal Fluid Proteins Following Disruption of the Blood-Epididymis Barrier by Novel 5α-Reductase Inhibitors" and "Exploration of the Mechanism by Which Icariin Intervenes in Dutasteride-Induced Epididymal Infertility Based on Androgen Regulation of Epididymal Function and Gene Expression," among others.